GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » 14-Day RSI

Alere (ALRPRB.PFD) 14-Day RSI : N/A (As of May. 18, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Alere 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-18), Alere's 14-Day RSI is N/A.

The industry rank for Alere's 14-Day RSI or its related term are showing as below:

ALRPRB.PFD's 14-Day RSI is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 51.1
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of Alere's 14-Day RSI

For the Diagnostics & Research subindustry, Alere's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alere's 14-Day RSI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Alere's 14-Day RSI falls into.



Alere  (NYSE:ALRPRB.PFD) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alere  (NYSE:ALRPRB.PFD) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Alere 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Alere's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Alere (ALRPRB.PFD) Business Description

Traded in Other Exchanges
N/A
Address
Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.
Executives
John Bridgen officer: Sr VP, Business Development 51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri officer: Senior VP, Global R&D 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell officer: Senior VP, Global Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers director C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant officer: VP, Controller, CAO 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan officer: SVP, Global Quality & Reg. 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp officer: Global Pres., Cardiometabolic 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani officer: Global Pres., Toxicology 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt director 51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon officer: SVP, Global Human Resources 4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy director C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg director C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453

Alere (ALRPRB.PFD) Headlines

From GuruFocus

Diamond Hill Capital Comments on Alere Inc

By Vera Yuan Vera Yuan 10-17-2014

5 Resilient Biotech Stocks to Buy for 2012

By Vatalyst.com Vatalyst.com 02-28-2012

Watsa Buys 19 Holdings in What He Calls 'Stock-Picker's Market'

By Holly LaFon Holly LaFon 11-14-2017

Corsair Capital's Analysis of Alere

By Canadian Value Canadian Value 03-06-2015

Mario Gabelli's Asset Fund Q3 2014 Commentary

By Vera Yuan Vera Yuan 11-21-2014

Alere's Shareholders Approve Merger With Abbott

By Alberto Abaterusso Alberto Abaterusso 10-23-2016

3 Investors Sitting on Huge Cash Stockpiles

By Holly LaFon Holly LaFon 11-21-2017

Diamond Hill Select Fund Third Quarter 2014 Commentary

By Vera Yuan Vera Yuan 10-17-2014

Corsair Capital's Investment Thesis on Alere Inc.

By Canadian Value Canadian Value 01-23-2014

Alere Reaches Settlement With SEC

By Alberto Abaterusso Alberto Abaterusso 09-29-2017